UPS expands temperature-controlled healthcare logistics with a $48 million investment across 27 facilities to support global pharmaceutical supply chains.

UPS has committed US$48 million to expand temperature-controlled logistics infrastructure across 27 facilities in Europe, Asia and the Americas, strengthening its healthcare supply chain capabilities. The UPS invests focuses on advanced cold-chain solutions to support the growing biologics market, where pharmaceutical products require precise handling, storage and transportation conditions. The expansion comes as demand rises for complex treatments including biologics, cell therapies and personalized medicines.

UPS Strengthens Global Cold-Chain Infrastructure

The investment will enhance UPS Healthcare’s cross-dock facilities, improving speed, short-term storage and reliability across air and ground transportation networks. The upgraded facilities will support products requiring different temperature conditions, including two to eight degrees Celsius, frozen environments and controlled room temperatures between 15 and 25 degrees Celsius.

Key highlights of the UPS healthcare logistics expansion include:

  • US$48 million investment across 27 facilities globally

  • Supports biologics and pharmaceutical supply chains

  • Expands temperature-controlled logistics capabilities worldwide

  • Improves shipment tracking and operational reliability

  • Strengthens healthcare distribution infrastructure globally

UPS operates more than 19.2 million square feet of cGMP and GDP-compliant healthcare distribution space across more than 200 countries and territories. The company has expanded its global capabilities through acquisitions, including Bomi Group, Frigo Trans, BPL and Andlauer Healthcare Group, integrating regional expertise with its wider logistics network.

Biologics Growth Drives Advanced Pharmaceutical Logistics

The pharmaceutical sector is undergoing a major transformation as biologics become increasingly important in modern healthcare. Cell and gene therapies, mRNA platforms and GLP-1 treatments require specialized logistics because temperature failures can impact product quality and patient access.

Market forecasts indicate that demand for temperature-sensitive biologics could reach US$39.1 billion by 2033. This growth is creating opportunities for logistics providers capable of delivering secure cold-chain management and regulatory compliance.

UPS Healthcare uses an integrated network and control tower monitoring system to track shipments continuously and identify risks. The company stated that these investments support stronger end-to-end supply chains, helping protect innovative treatments and improve healthcare delivery worldwide.

Thus, Business Fortune is of the view that UPS’s investment strengthens healthcare logistics capabilities while supporting the future growth of biologics worldwide.

FAQs

What is UPS investing in healthcare logistics?

UPS is investing US$48 million in temperature-controlled infrastructure.

Why are biologics changing pharmaceutical logistics?

Biologics require specialised storage and transportation conditions.

How many UPS facilities are included in the expansion?

The investment covers 27 facilities across global markets.

What temperature ranges do UPS facilities support?

Facilities support refrigerated, frozen and controlled room temperatures.

How does UPS improve pharmaceutical supply chain safety?

UPS uses integrated monitoring and logistics management systems.